Prosecution Insights
Last updated: April 19, 2026
Application No. 18/210,977

FLAVOR BANDING OF CAPSULES

Non-Final OA §102§103§112
Filed
Jun 16, 2023
Examiner
PACKARD, BENJAMIN J
Art Unit
1612
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
L Perrigo Company
OA Round
1 (Non-Final)
66%
Grant Probability
Favorable
1-2
OA Rounds
2y 11m
To Grant
82%
With Interview

Examiner Intelligence

Grants 66% — above average
66%
Career Allow Rate
869 granted / 1317 resolved
+6.0% vs TC avg
Strong +16% interview lift
Without
With
+16.1%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
44 currently pending
Career history
1361
Total Applications
across all art units

Statute-Specific Performance

§101
1.1%
-38.9% vs TC avg
§103
44.2%
+4.2% vs TC avg
§102
18.6%
-21.4% vs TC avg
§112
14.5%
-25.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1317 resolved cases

Office Action

§102 §103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-25 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claims 1 and 12 recited the capsule needs to comply with “the requirements of 21 C.F.R. Section 211.132”, but like claiming a trademark, the code may change over time. As such, what may be claimed now could change later based on potential modifications of the Federal Rules. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1-4, 6-8, and 11 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Warner (EP 0426428). Warner teaches a dried formation having a flavor delivery system comprising 65.5% w/w gum arabic, 12% w/w acesulfame K, 20% w/w peppermint, and 2.5% emulsifier. Claims 1-8 and 11 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by McNeil (WO 2007/133140). McNeil discloses an oral film composition comprising 51.3% w/w gelling agent consisting of pullulan, xanthan gum, locust bean gum, carrageenan and pectin, 1.53% w/w polysorbate 80 and Atmos 300, 32.7% w/w flavor system consisting of 8.3% sweeteners (sucralose or sorbitol) and 24.4% flavors. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1-25 are rejected under 35 U.S.C. 103 as being unpatentable over Derwent (“Band seal liquid for hard gelatin capsule- contains gelatin, edible surfactant and water, XP002189839”) in view of Warner (EP 0426428) or McNeil (WO 2007/133140). Derwent teaches a band seal liquid for hard gelatin capsules containing 15-30wt% gelatin, 0.1-10wt% edible surfactant, and water, where edible surfactants include polyoxyethylene sorbitan fatty acid ester, glycerin fatty acid ester, sucrose fatty acid ester, sorbitan fatty acid ester, propylene glycol fatty acid ester, saponin, or soybean lipid. Derwent does not teach the flavor component. It would have been obvious to one of ordain skill in the art to modify the band seal liquid of Derwent using the formulations disclosed in either Warner or McNeil, where they are all dried gelling agents. See MPEP 2144.06. With regards to the tamper evident limitation, where the primary reference teaches the formulations are used to seal a hard capsule system, it would be obvious to make sure it meets the legal requirements for pharmaceutical sales, which include tamper evident properties. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to BENJAMIN J PACKARD whose telephone number is (571)270-3440. The examiner can normally be reached Mon 2-6pm and Tues-Fri (9am-6pm + mid-day flex). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sahana Kaup can be reached at (571) 272-6897. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BENJAMIN J PACKARD/ Primary Examiner, Art Unit 1612
Read full office action

Prosecution Timeline

Jun 16, 2023
Application Filed
Jan 08, 2026
Non-Final Rejection — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12589111
PT(IV) CHEMOTHERAPEUTIC PRODRUG AND CONTROLLED RELEASE THEREOF FOR TREATMENT OF TUMORS
2y 5m to grant Granted Mar 31, 2026
Patent 12582745
ADHESIVE COMPOSITION FOR HARD TISSUE REPAIR
2y 5m to grant Granted Mar 24, 2026
Patent 12583865
Biologically Active Taxane Analogs and Methods of Treatment by Oral Administration
2y 5m to grant Granted Mar 24, 2026
Patent 12582586
Oral Care Compositions
2y 5m to grant Granted Mar 24, 2026
Patent 12576105
COMPOSITIONS FOR TREATING JOINT OR CONNECTIVE TISSUE DISEASE COMPRISING DEXTRAN OR POLOXAMER
2y 5m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
66%
Grant Probability
82%
With Interview (+16.1%)
2y 11m
Median Time to Grant
Low
PTA Risk
Based on 1317 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month